2020
The ‘new’ Race launched with the announcement of the Three Pillar Strategy
Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene
Bisantrene is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be an important to the progression of a wide range of cancers. Race Oncology is first exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers.
The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers and is investigating its use in these areas.
Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Bisantrene.
Review our plans under the Three Pillar strategy via our 2020 strategic update which was released to the ASX on 30 November 2020.
Race is led by a seasoned team and Board, supported by a network of key opinion leaders and collaborators. See our leadership team here.